MEDICAMEQ

Medicamen Biotech Share Price

 

 

Start SIP in MEDICAMEQ

Start SIP

Performance

  • Low
  • ₹360
  • High
  • ₹385
  • 52 Week Low
  • ₹293
  • 52 Week High
  • ₹630
  • Open Price₹385
  • Previous Close₹381
  • Volume43,775

Investment Returns

  • Over 1 Month -10.22%
  • Over 3 Month + 3.97%
  • Over 6 Month -14.1%
  • Over 1 Year -39.74%

Smart Investing Starts Here Start SIP with Medicamen Biotech for Steady Growth!

Invest Now

Medicamen Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 48.6
  • PEG Ratio
  • 1.1
  • Market Cap Cr
  • 494
  • P/B Ratio
  • Average True Range
  • 15.57
  • EPS
  • 7.89
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 9.96
  • RSI
  • 36.87
  • MFI
  • 51.57

Medicamen Biotech Financials

Medicamen Biotech Technicals

EMA & SMA

Current Price
₹364.30
-16.8 (-4.41%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹390.64
  • 50 Day
  • ₹377.05
  • 100 Day
  • ₹377.07
  • 200 Day
  • ₹399.66

Resistance and Support

370 Pivot Speed
  • R3 404.50
  • R2 394.90
  • R1 379.60
  • S1 354.70
  • S2 345.10
  • S3 329.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Medicamen Biotech Ltd specializes in the manufacturing and marketing of pharmaceutical formulations, including injectables, tablets, and syrups. The company serves domestic and international markets, focusing on quality, innovation, and regulatory compliance in the healthcare sector.

Medicamen Biotech has an operating revenue of Rs. 164.97 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of 6% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Medicamen Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-12 Quarterly Results
2025-05-30 Audited Results & Final Dividend
2025-02-26 Preferential issue of shares
2025-02-11 Quarterly Results
Date Purpose Remarks
2025-09-19 FINAL Rs.1.00 per share(10%)Final Dividend (RD & XD dates revised)
View Medicamen Biotech Dividend History Arrow

Medicamen Biotech F&O

Medicamen Biotech Shareholding Pattern

40.46%
0.05%
33.34%
26.15%

Medicamen Biotech FAQs

Medicamen Biotech share price is ₹364 As on 08 December, 2025 | 18:38

The Market Cap of Medicamen Biotech is ₹494.2 Cr As on 08 December, 2025 | 18:38

The P/E ratio of Medicamen Biotech is 48.6 As on 08 December, 2025 | 18:38

The PB ratio of Medicamen Biotech is 2.3 As on 08 December, 2025 | 18:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23